Table 1 JAK2 exon 19 SNP analysis of PCR... | American Society of Hematology

Table 1

JAK2 exon 19 SNP analysis of PCR products from 11 patients with JAK2-V617F mutant–positive ET

Patient	% Mutant JAK2, neutrophil DNA	SNP allele A:G ratio in V617F PCR products,* neutrophil DNA	% SNP allele A V617F+ clones† (no. clones examined)
1	100	A	N/A
2	13	A>G	N/A
3	40	A>G	N/A
4	25	A<G	N/A
5	24	A=G	N/A
6	42	A>G	N/A
7a (Oct. 2000)	20	A>G	82% (33)
7b (Dec. 2004)	33	A>G	Platelets 78% (27)
8	26	A<G	41% (31)
9	14	N/A	76% (29)
10a (July 2000)	27	A>G	77% (33)
			Platelets 72% (29)
10b (June 2002)	20	A>G	87% (31)
			CD34⁺ 78% (32)
11	11	A<G	23% (31)

Patient	% Mutant JAK2, neutrophil DNA	SNP allele A:G ratio in V617F PCR products,* neutrophil DNA	% SNP allele A V617F+ clones† (no. clones examined)
1	100	A	N/A
2	13	A>G	N/A
3	40	A>G	N/A
4	25	A<G	N/A
5	24	A=G	N/A
6	42	A>G	N/A
7a (Oct. 2000)	20	A>G	82% (33)
7b (Dec. 2004)	33	A>G	Platelets 78% (27)
8	26	A<G	41% (31)
9	14	N/A	76% (29)
10a (July 2000)	27	A>G	77% (33)
			Platelets 72% (29)
10b (June 2002)	20	A>G	87% (31)
			CD34⁺ 78% (32)
11	11	A<G	23% (31)

ET indicates essential thrombocythemia; PCR, polymerase chain reaction; and N/A, not assessed.

Visual estimate of alleles from gel.

Neutrophil samples unless otherwise indicated.